<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161459">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920295</url>
  </required_header>
  <id_info>
    <org_study_id>3196568</org_study_id>
    <nct_id>NCT01920295</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation as First-line Therapy</brief_title>
  <acronym>C-frost</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Yuksek Ihtisas Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuksek Ihtisas Hospital</source>
  <oversight_info>
    <authority>Turkey: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cryoballoon ablation of paroxysmal atrial fibrillation can be used as first-line therapy
      compared to second choice after failed medical therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)</measure>
    <time_frame>12 months from the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>At prespecified interval of 12th month from the index procedure occurence of Recurrent atrial fibrillation, atrial flutter and atrial tachycardia ( Number of Participants with Recurrent atrial fibrillation, atrial flutter and atrial tachycardia )was assessed using ambulatory holter ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)</measure>
    <time_frame>3 months from the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>At prespecified interval of 3rd month from the index procedure occurence of Recurrent atrial fibrillation, atrial flutter and atrial tachycardia ( Number of Participants with Recurrent atrial fibrillation, atrial flutter and atrial tachycardia )was assessed using ambulatory holter ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)</measure>
    <time_frame>6 months from the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>At prespecified interval of 6th month from the index procedure occurence of Recurrent atrial fibrillation, atrial flutter and atrial tachycardia ( Number of Participants with Recurrent atrial fibrillation, atrial flutter and atrial tachycardia )was assessed using ambulatory holter ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)</measure>
    <time_frame>9 months from the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>At prespecified interval of 9th month from the index procedure occurence of Recurrent atrial fibrillation, atrial flutter and atrial tachycardia ( Number of Participants with Recurrent atrial fibrillation, atrial flutter and atrial tachycardia )was assessed using ambulatory holter ECG monitoring</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoballoon ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoballoon after medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoballoon ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoballoon as first-line therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoballoon ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoballoon after failed drug therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cryoballoon ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoballoon ablation</intervention_name>
    <arm_group_label>Cryoballoon ablation</arm_group_label>
    <arm_group_label>Cryoballoon after medical therapy</arm_group_label>
    <arm_group_label>Cryoballoon as first-line therapy</arm_group_label>
    <arm_group_label>Cryoballoon after failed drug therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  paroxysmal atrial fibrillation, symptomatic

        Exclusion Criteria:

          -  atrial fibrillation other than PAF, asymptomatic, previous AF ablation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yuksek Ihtisas Heart-Education and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yuksek Ihtisas Hospital</investigator_affiliation>
    <investigator_full_name>Serkan Cay</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
